Currently, there are 115.21M common shares owned by the public and among those 110.58M shares have been available to trade.
The company’s stock has a 5-day price change of 41.32% and 30.53% over the past three months. CHRS shares are trading -48.65% year to date (YTD), with the 12-month market performance down to -25.65% lower. It has a 12-month low price of $0.66 and touched a high of $3.70 over the same period. CHRS has an average intraday trading volume of 2.95 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 71.60%, 81.12%, and 5.97% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Coherus Biosciences Inc (NASDAQ: CHRS) shares accounts for 66.08% of the company’s 115.21M shares outstanding.
It has a market capitalization of $197.01M and a beta (3y monthly) value of 0.85. The earnings-per-share (ttm) stands at -$0.10. Price movements for the stock have been influenced by the stock’s volatility, which stands at 18.69% over the week and 15.48% over the month.
Earnings per share for the fiscal year are expected to increase by 113.96%, and -281.24% over the next financial year.
Looking at the support for the CHRS, a number of firms have released research notes about the stock. UBS stated their Neutral rating for the stock in a research note on August 16, 2024, with the firm’s price target at $4-$1.50. Robert W. Baird coverage for the Coherus Biosciences Inc (CHRS) stock in a research note released on November 17, 2023 offered a Outperform rating with a price target of $11. Maxim Group was of a view on November 08, 2023 that the stock is Hold, while Citigroup gave the stock Buy rating on July 24, 2023, issuing a price target of $12. Truist on their part issued Buy rating on May 01, 2023.
